CredenceResearch Logo

Drug commercialization research

Understand the path from diagnosis to sustained treatment before you commit launch resources

Regulatory approval does not guarantee uptake. A drug succeeds commercially when the right patients are diagnosed, referred, prescribed, able to access treatment and stay on it. Credence Research maps that journey for your indication and tests where patients are lost, so launch plans, positioning and support programs address the real barriers.

Discuss your commercialization questionSee what the outputs include

The patient journey, and where evidence on patient loss is usually thinnest

1Symptoms and diagnosisDiagnosis rates
2Referral to specialistReferral pathways
3Treatment decisionSwitching triggers
4Access and affordabilityPayer restrictions
5Adherence and persistenceReasons for stopping

Marked items are rarely visible in published data. They usually need prescriber, payer or patient research.

Decisions that bring commercialization teams to us

These decisions usually fall in the two to three years before and after approval.

Estimating commercial potential

You need a forecast that reflects how patients actually move from diagnosis to treatment.

Choosing target prescribers and patients

You need to know which specialists and patient groups to prioritize at launch.

Positioning against competitors

You need to understand what prescribers value in current treatments and where yours fits.

Planning access and pricing

You need to anticipate payer requirements and restrictions.

Designing patient support

You need to know why patients stop treatment and what support would help.

Informing late-stage development

You want commercial input on endpoints and comparators that matter to prescribers and payers.

Start with what you already know

Most teams have trial data, a target product profile and a draft forecast. What usually remains uncertain is how many patients are diagnosed and referred, how prescribers will choose between options, and what payers will require.

Questions commercialization research can investigate

Patients

  • How many patients are diagnosed, referred and treated?
  • Where in the journey are patients lost?
  • Why do patients stop treatment?

Prescribers

  • Which specialists treat the condition, and how do they choose therapy?
  • What evidence would lead them to switch?
  • Which messages resonate?

Payers and access

  • What restrictions are likely, such as prior authorization or step therapy?
  • What price range do comparable therapies achieve?
  • How long does access take after approval?

Forecast

  • What uptake is realistic given the patient journey?
  • Which assumptions most affect revenue?
  • How would competitor launches change the outlook?

What public sources can tell you, and what needs further validation

Epidemiology studies, treatment guidelines, published assessment decisions and competitor disclosures describe the context. They say little about individual prescribing decisions or reasons patients stop.

Where desk research is often sufficient, and where decisions usually need more evidence
TopicDesk research can often establishWhat often remains unresolvedHow it can be tested
Patient numbersPrevalence and incidenceDiagnosed, referred and treated patientsPatient funnel model checked with clinicians
Prescriber behaviorGuidelinesActual treatment choices and switching triggersPrescriber interviews or surveys
Payer responsePublished assessment decisionsLikely restrictions for a new drugPayer and market access interviews
PersistenceSome published studiesReasons for stopping in your indicationPatient or patient advocacy research
Competitor positioningLabels and promotional claimsHow prescribers perceive competitorsPrescriber interviews

AI tools can summarize literature, guidelines and competitor materials quickly. Prescriber intent, payer response and patient experience need direct evidence from those groups.

How evidence gaps translate into research

This example is illustrative. It shows how a study could be designed and does not describe a specific client engagement.

Specialty drug launch in a rare condition

Illustrative example
Business question
A company expects approval for a treatment in a rare condition and needs to plan its launch.
Evidence gap
Prevalence is published, but diagnosis rates, referral patterns and specialist concentration are unknown.
Research method
Patient funnel modeling, interviews with treating specialists and patient advocacy groups, and payer interviews.
Deliverable
A patient journey map with loss points, a prescriber targeting list by specialty and a forecast with ranges.
Decision supported
Launch sequencing, field force size and priorities for patient support programs.

Our research approach

We combine published evidence with research among prescribers, payers and, where appropriate, patients.

Methods, what they are used for and their limits
MethodPurposeLimitation
Patient journey mappingIdentify where patients are lostRelies on several data sources of varying quality
Prescriber interviews and surveysTest treatment choices and positioningStated intent can differ from prescribing
Payer and market access interviewsAnticipate access conditionsCannot predict specific decisions
Patient and advocacy researchUnderstand experience and reasons for stoppingSubject to ethics and privacy requirements
Forecast modelingProject uptake from the patient journeyShown as ranges with assumptions

We do not provide medical, promotional compliance or regulatory advice, and research involving patients follows applicable ethics and privacy requirements.

What you receive

Deliverables depend on scope, and not every study includes every output. We agree on outputs during scoping.

  • Patient journey map

    Stages from symptoms to persistence, with estimated patient loss at each.

    Use it to target the barriers that limit uptake.

  • Prescriber segmentation

    Specialists and settings ranked by patient volume and openness to new treatment.

    Use it to focus field teams.

  • Positioning assessment

    How prescribers view current options and where your drug fits.

    Use it to refine messages and evidence plans.

  • Access landscape

    Likely restrictions, price benchmarks and timelines by market.

    Use it to plan pricing and access.

  • Commercial forecast

    Uptake and revenue under stated assumptions.

    Use it to set launch targets and budgets.

Published report or custom research?

Published pharmaceutical market reports can describe the treatment landscape and market size. Commercialization research is more useful when your decisions depend on prescriber behavior, patient loss or payer response in your indication.

Is commercialization research right for your decision?

  • You are within a few years of approval or launch.
  • You need to prioritize prescribers, patients or markets.
  • Your forecast depends on diagnosis, access or persistence assumptions.
  • You have a launch planning milestone ahead.

If most of these apply, a scoping conversation is likely to be productive. If not, a published report or a short discussion about scope may be a better first step.

Discuss your commercialization question

Frequently asked questions

Discuss your commercialization question

Tell us about the product, indication and launch timing.

What happens next

A member of our research team reviews your brief and contacts you to discuss scope and approach. If existing research can answer your question, we will point you to it.

Phone